At a Glance
| Indication | locally advanced or metastatic non-small cell lung cancer |
| Drug | Zegfrovy |
| Mechanism of Action | EGFR inhibitor |
| Company | AstraZeneca |
| Trial Phase | Phase 3 |
| Trial Acronym | WU-KONG28 |
| Category | Corporate & Strategic |
| Sub Category | Licensing Agreement |
| Therapeutic Area | Oncology |
| Deal Value | up to $1.5 billion |
| Upfront Payment | $600 million |
| Milestone Payments | up to $900 million |
| Licensed Territory | worldwide |
| Approved Market/Region | U.S., China |
| Approval Type | accelerated FDA approval |
| Approval Date | July 2025 |
| Primary Endpoint | Progression-Free Survival (PFS) |
| Risk Reduction (PFS) | 35% |
| Objective Response Rate (ORR) | nearly 60% versus 31% in chemotherapy controls |
AstraZeneca Licenses Dizal's Lung Cancer Drug Zegfrovy for $1.5B
AstraZeneca has secured an exclusive worldwide license to Dizal Pharmaceutical’s oral lung cancer drug, Zegfrovy, in a deal valued at up to $1.5 billion. The agreement includes an upfront payment of $600 million, with an additional $900 million earmarked for development, regulatory, and sales-related milestones, plus tiered royalties on global sales. Zegfrovy, an EGFR inhibitor, received accelerated FDA approval in July 2025 and is also approved in China for locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have progressed on or after platinum-based chemotherapy. Dizal is currently seeking regulatory decisions to expand Zegfrovy's use to the frontline NSCLC setting.
- AstraZeneca has committed a substantial investment of up to $1.5 billion to gain exclusive worldwide rights to Zegfrovy. This includes an immediate $600 million upfront payment to Dizal Pharmaceutical, alongside potential milestone payments totaling up to $900 million tied to development, regulatory achievements, and sales performance. Dizal will also benefit from tiered royalties on future global sales.
- Zegfrovy, an orally available EGFR inhibitor, has already achieved accelerated FDA approval in July 2025 and is approved in China for metastatic NSCLC patients who have progressed after platinum-based chemotherapy. Dizal is actively pursuing further regulatory approvals in both the U.S. and China to expand Zegfrovy's indication to the first-line NSCLC setting, indicating significant market expansion potential.
- Clinical data from the Phase 3 WU-KONG28 study demonstrated Zegfrovy's efficacy in the first-line setting, showing a significant prolongation of median progression-free survival (PFS) and a 35% reduction in the risk of disease progression or death compared to chemotherapy. The drug also achieved a superior objective response rate (ORR) of nearly 60% versus 31% in chemotherapy controls, highlighting its clinical benefit.
Zegfrovy's Place in the EGFR Inhibitor Landscape
Several anti-EGFR antibodies are currently under investigation for metastatic colorectal cancer (mCRC), sharing the same mechanism of action as Zegfrovy — targeted blockade of the epidermal growth factor receptor. The agents identified span both established therapies and investigational combinations, evaluated across a range of trial intervention models from monotherapy to multi-agent regimens.
| Drug | Drug Class | Indication | Intervention Model | Trial/Context |
|---|---|---|---|---|
| Cetuximab | Anti-EGFR monoclonal antibody | Metastatic colorectal cancer (mCRC) | Monotherapy; combination with chemotherapy (e.g., FOLFIRI) — first-line and later-line settings | Multiple phase 2/3 RCTs; 5 trials identified in literature search |
| Panitumumab | Anti-EGFR monoclonal antibody | Metastatic colorectal cancer (mCRC) | Monotherapy; combination with chemotherapy — first-line and later-line settings | 1 trial identified in literature search; network meta-analysis across 7 phase 2 RCTs (n=1,286) |
| Tomuzotuximab | Glyco-optimized anti-EGFR monoclonal antibody | Refractory mCRC; EGFR-positive metastatic solid tumors | Combination with gatipotuzumab (TA-MUC1-targeting antibody) at 1,200 mg Q2W | GATTO study (NCT03360734); phase I; primary phase (n=20) + expansion phase (n=32) |
| Cetuximab + Pembrolizumab / Nivolumab | Anti-EGFR + immune checkpoint inhibitor | mCRC | Combination (EGFR inhibitor + ICI) | Retrospective chart review; cetuximab-pembrolizumab (72%) or cetuximab-nivolumab (28%) |
| Anti-EGFR antibodies (class) | Anti-EGFR monoclonal antibodies | mCRC (RAS wild-type) | Combination with fluoropyrimidine monotherapy; continuous chemotherapy doublet + anti-EGFR until progression; maintenance strategies | Network meta-analysis of 7 randomized phase 2 trials in RAS wild-type advanced CRC |
Frequently Asked Questions
What is the clinical positioning of Zegfrovy in the treatment of locally advanced or metastatic NSCLC?
Zegfrovy offers a targeted therapeutic option for specific subsets of patients with locally advanced or metastatic non-small cell lung cancer. Its mechanism of action is designed to interfere with key pathways driving tumor growth and progression. This positions it as a valuable agent, particularly in cases where other standard therapies may have limited efficacy or are not indicated.
Are there specific biomarkers or patient characteristics that predict response to Zegfrovy in NSCLC?
Patient selection for Zegfrovy in NSCLC is guided by the presence of specific molecular alterations within the tumor. These biomarkers are critical for identifying individuals most likely to derive clinical benefit from the therapy. Comprehensive genomic profiling is typically employed to confirm eligibility and optimize treatment outcomes.
What are the common mechanisms of resistance to Zegfrovy in non-small cell lung cancer?
Resistance to Zegfrovy in NSCLC can arise through various mechanisms, including the development of secondary mutations in the drug target or activation of bypass signaling pathways. These adaptive changes allow cancer cells to circumvent the therapeutic effects of the drug. Understanding these resistance mechanisms is crucial for developing subsequent treatment strategies and combination approaches.
What unmet needs does Zegfrovy address in the management of locally advanced or metastatic NSCLC?
Zegfrovy addresses the need for effective targeted therapies in specific patient populations with locally advanced or metastatic NSCLC who may have limited treatment options. It provides a novel approach for patients whose tumors harbor particular genetic drivers. This contributes to improving progression-free survival and overall quality of life for these individuals.
References
- [1] Srivastava S, Anand A et al.. Precision Medicine in Colorectal Cancer: Targeted Therapies and Biomarker Insights. Current cancer drug targets. 2026. 39878113
- [2] Tang S, Li Z et al.. A potential new role of ATM inhibitor in radiotherapy: suppressing ionizing Radiation-Activated EGFR. International journal of radiation biology. 2020 Apr. 31859574
- [3] Tripathi PK, Mittal KR et al.. KRAS Pathways: A Potential Gateway for Cancer Therapeutics and Diagnostics. Recent patents on anti-cancer drug discovery. 2024. 37038676
- [4] Pinto C, Barone CA et al.. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. The oncologist. 2011. 21273511
- [5] Benhaim L, Loupakis F et al.. Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?. Journal of hepato-biliary-pancreatic sciences. 2012 Sep. 22735932
- [6] Françoso A, Simioni PU. Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. Drug design, development and therapy. 2017. 28138221
- [7] Kawczak P, Bączek T. Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib. Journal of clinical medicine. 2026 Mar 20. 41899309
- [8] Piront P, Van Daele D et al.. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab]. Revue medicale de Liege. 2009 May-Jun. 19642458
- [9] Berg M, Soreide K. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discovery medicine. 2012 Sep. 23021375
- [10] Rosati G, Montrone M et al.. An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer. Journal of clinical medicine. 2022 Nov 30. 36498683
- [11] Kargbo RB. Potent PROTACs Targeting EGFR Mutants in Drug Discovery. ACS medicinal chemistry letters. 2022 Dec 8. 36518691
- [12] Sablin MP, Dreyer C et al.. [Targeted therapies in colorectal cancer]. La Revue du praticien. 2010 Oct 20. 21197741
- [13] Mohamed A, Twardy B et al.. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results. Journal of gastrointestinal cancer. 2019 Jun. 29388061
- [14] Kim JE, Kim KK et al.. MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines. Journal of Cancer. 2017. 28819429
- [15] Bronte G, Cicero G et al.. Monoclonal antibodies in gastrointestinal cancers. Expert opinion on biological therapy. 2013 Jun. 23441760
- [16] Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clinical therapeutics. 2010 Mar. 20399983
- [17] Ličar A, Cerkovnik P et al.. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Medical oncology (Northwood, London, England). 2011 Dec. 20645028
- [18] Fish-Steagall A, Searcy P et al.. Clinical experience with anti-EGFR therapy. Seminars in oncology nursing. 2006 Feb. 16616282
- [19] Ochsenreither S, Fiedler WM et al.. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors. ESMO open. 2022 Apr. 35397434
- [20] Kale IP, McCauley EM et al.. Cutaneous adverse effects of combination epidermal growth factor receptor inhibitor and immune checkpoint inhibitor cancer therapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2025 Jun 2. 40455297
Contact Us
📍
Address
One Research Ct, Suite 450
Rockville, MD 20850
✉️
For General Inquiry
info@pienomial.com
